Drug Profile
SSR 244738
Alternative Names: SSR-244738Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antineoplastics
- Mechanism of Action Cell cycle protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 06 Jul 2007 Clinical data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and pharmacokinetics sections
- 14 May 2007 Phase-I clinical trials in Cancer in Europe (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis